| Date Filed | Type | Description |
| 10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
3
| Bain Capital Life Sciences Investors, LLC (10% Owner) has filed a Form 3 on Annexon, Inc. |
| 05/30/2023 |
4
| Bain Capital Life Sciences Investors, LLC (10% Owner) has filed a Form 4 on Annexon, Inc.|
Txns:
| Bought 300,000 shares
@ $2.1324, valued at
$639.7k
|
|
| 05/30/2023 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. reports a 5.5% stake in Annexon, Inc. |
| 05/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/15/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2023 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for Annexon, Inc. |
| 02/14/2023 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for X4 Pharmaceuticals, Inc. |
| 11/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/17/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/15/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/08/2022 |
SC 13D/A
| Bain Capital Life Sciences Fund, L.P. reports a 4.5% stake in ARCUTIS BIOTHERAPEUTICS, INC. |
| 05/27/2022 |
SC 13D/A
| Bain Capital Life Sciences Fund, L.P. reports a 5.3% stake in ARCUTIS BIOTHERAPEUTICS, INC. |
| 05/16/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2022 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for X4 Pharmaceuticals, Inc. |
| 02/14/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/27/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/11/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/21/2021 |
4
| Bain Capital Life Sciences Investors, LLC (10% Owner) has filed a Form 4 on RAPID MICRO BIOSYSTEMS, INC.|
Txns:
| Converted 6,999,998 shares
@ $0
Converted 1,334,562 shares
@ $0
Bought 100,000 shares
@ $20, valued at
$2M
Converted 35,000,001 options to buy
@ $0
Converted 6,672,819 options to buy
@ $0 |
|
| 07/14/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/11/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/17/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 03/26/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/19/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G
| Bain Capital Life Sciences Fund, L.P. reports a 7.7% stake in Annexon, Inc. |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
|